Improvement of Resveratrol Effects When Combined with Rice Oil in Rat Models of Inflammation
| Autor: | Rodrigo B. M. Silva, Izaque de Sousa Maciel, Alice Ribeiro, Andressa Bernardi, Gabriel Rübensam, André Arigony Souto, Maria M. Campos, Fernanda Bueno Morrone |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male medicine.medical_treatment Drug Compounding Immunology Freund's Adjuvant Anti-Inflammatory Agents Arthritis Inflammation Pharmacology Resveratrol Carrageenan Rice Bran Oil 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine In vivo Edema medicine Immunology and Allergy Animals Rats Wistar business.industry medicine.disease Disease Models Animal 030104 developmental biology Cytokine chemistry 030220 oncology & carcinogenesis Cytokines Polyarthritis Joints medicine.symptom Inflammation Mediators business Adjuvant |
| Zdroj: | Inflammation. 43(1) |
| ISSN: | 1573-2576 |
| Popis: | This study investigated the effects of systemic treatment with a new formulation of resveratrol (RSV) vehicled in rice oil (RSVO) in experimental rat models of inflammation. Male Wistar rats were evaluated in the following in vivo models: carrageenan-induced acute edema, complete Freund’s adjuvant (CFA)-evoked sub-chronic edema, and CFA-induced polyarthritis. The animals were treated orally with RSVO (10–15 mg/kg) or RSV (100–200 mg/kg), depending on the experimental protocol. RSV was more effective than RSVO in carrageenan-elicited acute edema when dosed in either prophylactic or therapeutic schemes of administration. However, the repeated RSVO administration, at 10-fold lower doses, exhibited superior anti-inflammatory actions in either the sub-chronic edema or the chronic polyarthritis model elicited by CFA, when compared with RSV. The novel formulation RSVO displayed a lower plasma biotransformation when compared with the RSV-treated group—46% versus 88% of metabolites, respectively. RSVO also prevented polyarthritis-related cartilage destruction, an effect that might rely on the inhibition of the pro-inflammatory cytokine interleukin-6 (IL-6), associated with an increase of the anti-inflammatory cytokine interleukin-10 (IL-10). Noteworthy, the long-term administration of RSVO did not elicit any gastrointestinal harm. Our study revealed that RSVO was notably effective in the long-term inflammatory and degenerative responses triggered by CFA. This innovative formulation might well represent a promising alternative for treating chronic inflammatory diseases, such as arthritis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink